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Abstract
Background: ATP-binding cassette sub-family G member 2 (ABCG2) is a semi-transport protein that plays a major
role in multidrug resistance. We aimed to evaluate the prognostic significance of ABCG2 expression in patients with
clear cell renal cell carcinoma.
Methods: From 2008 to 2013, 120 patients with clear cell kidney cancer underwent surgery with paraffin-embedded
specimens and necessary clinical information available. Immunohistochemistry staining was performed to grade the
expression of ABCG2 as ABCG2(−): less than 10% of tumor cells stained; ABCG2(+): weak membrane staining; and
ABCG2(++): moderate or strong membrane staining. The overall survival was analyzed using Kaplan-Meier method.
Multivariable Cox regression evaluated the independent predictors for overall survival.
Results: ABCG2(−) was diagnosed in 57 (48%) patients, ABCG2(+) in 52 (43%) patients, and ABCG2 (++) in 11(9.2%)
patients. ABCG2 expression significantly correlated with the five-year survival (p < 0.001) and distant metastasis (p = 0.001).
In the multivariable analysis, besides Fuhrman grade, the ABCG2 expression was an independent prognostic marker for
overall survival (p < 0.001) when incorporating other relevant tumor and clinical parameters (HR = 3.84, 95% CI: 1.92–7.70).
Conclusion: The current data suggests that ABCG2 may serve as a prognostic marker for overall survival in patients with
clear cell renal cell carcinoma. Further studies with large cohorts of patients will be essential for validating these findings
and defining the clinical utility of ABCG2 in the patient population.
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Background
Renal cell carcinoma (RCC) is the most common type of
malignant renal cancer in adults, responsible for approxi-
mately 90–95% of the diagnosed cases [1]. Approximatelys,
25–30% patients present metastasis at the time of diagnosis
and 30% of the patients relapse after renal surgery [2]. To
date, surgery is the primary treatment for RCC, and the
five-year survival rate is 65–90%; however, the outcome is
considerably reduced in metastatic cases [3]. RCC is
relatively resistant to radiotherapy and chemotherapy
with only a 4–5% response rate [4, 5]. Some cases respond
to immunotherapy with a 30% response rate [6]. By 2013,
with the advancement in targeted therapy, such as Sunitinib
and Sorafenib, the average survival time was improved from
12 months to 22 months in patients with metastatic RCC
[7, 8]. However, the five-year overall survival for metastatic
RCC remains <10% [3].
ATP-binding cassette sub-family G member 2 (ABCG2)
was first named as Breast Cancer Resistance Protein in
the 1990s when it was discovered in MCF-7 breast cancer
cell line co-selected for doxorubicin in the presence of
verapamil [9]. Following its discovery, ABCG2 was cloned,
characterized, and added as the second member of the G
subfamily of ABC transporters, as a semi-transport
protein [10]. ABCG2 has main effect on effluxing drugs at
major physiological barriers, such as blood-brain, blood-
testis and maternal-fetal barriers. Similar function of ABCG2
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is validated in effluxing of xenobiotics at small intestine and
kidney proximal tubule brush borders. ABCG2 transports a
wide variety of substrates including several anticancer agents
and is one of the most significant contributors to multidrug
resistance in cancer cells [10, 11].
Although ABCG2 has been studied in diverse fields,
the precise function and effect in RCC are yet poorly
understood [12]. Due to the heterogeneous high expression
pattern of ABCG2 in the kidney, researchers have spec-
ulated that this protein may be actively involved in drug
resistance, leading to failure of chemotherapeutic treatments
[13, 14]. Clinically, whether ABCG2 expression could pre-
dict overall survival for RCC has not been well studied.
Thus, we aimed to evaluate the correlation between ABCG2
expression and overall survival of patients with clear
cell RCC managed by renal surgery.
Methods
Patient samples
Following approval by the Ethics Committee of Ruijin
Hospital, the kidney surgery Registry database was used
to identify patients who were managed with renal cancer
surgery from 2008 to 2013. Written informed consent
was obtained from all the patients. During this time, 120
patients with complete recorded information and paraffin
sections were enrolled in our study, and followed-up for a
minimum of three years. Decisions about radical nephrec-
tomy (114 cases) or partial nephrectomy (6 cases) were
made by the primary surgeon based on individual tumor
and patient conditions. After surgery, 101 patients without
metastasis at the initial diagnosis received interferon
alpha for one year as the routine sequential treatment.
In addition, Sorafenib or Sunitinib was administered in
the other 19 patients with metastatic RCC until intolerable
side-effects of drugs or disease progression. The main ex-
clusion criteria from this analysis were a lack of a complete
recorded file and unavailability of paraffin sections.
Evaluation of ABCG2
Immunohistochemistry staining (IHC) is one of the most
widely used methods for the identification and assessment
of prognostic biomarkers. In the present study, standard
IHC protocol was used to detect the expressions of
ABCG2 according to the manufacturer’s instructions
[14, 15]. Samples of renal cancer were collected, fixed
in 10% formalin, and embedded in paraffin wax. Monoclonal
antibody against ABCG2 (#271–396, Santa Cruz) was
used in this study [14, 15].
Tissue sections were prepared from the formalin-fixed-
paraffin-embedded specimens. Antigen retrieval of RCC
was performed by incubating the slides in Tris-EDTA
buffer (pH 8.4) at 99 °C for 60 min. The endogenous
peroxidase activity was inactivated in methanol with 3%
H2O2. Then, the slides were incubated with primary
antibody for 60 min and secondary antibody for 8 min,
followed by DAB chromagen staining for 8 min. All the
procedures were performed using stainer (BenchMark
XT, Ventana) and the slides were scanned (Ventana
iScan Coreo) [14].
The IHC results were quantified by qualified and experi-
enced pathologists. Each stained section was independ-
ently evaluated by two pathologists using standard criteria
from the WHO classification. The third independent
pathologist would adjudicate the stained section if there
was different opinions. The staining of BXP-21 was scored
as negative if less than 10% of the tumor cells were stained
[14]. The intensity of the positive staining of ABCG2 was
graded into two categories: ABCG2(+) for weak mem-
brane staining of tumor cells; ABCG2 (++) for moderate
or strong membrane staining of tumor cells.
TCGA database analysis
The RNA-seq data was downloaded from TCGA database
and analyzed by the cBioPortal-MSKCC tool. ABCG2
expression was compared between clear cell RCC and
all the other genitourinary tumors available from TCGA
database using unpaired t-tests and nonparametric test
(Additional file 1: Fig. S1). Significance was considered if
p < 0.05.
Statistical analysis
Continuous variables were expressed as a median and
interquartile range (IQR) and compared using Mann-
Whitney test. The categorical variables were compared
by chi-square and Fisher’s exact tests. The primary end-
point was defined as the overall survival, which was ini-
tiated from the date of renal cancer surgery until death
or the end of follow-up. Survival curves were plotted by
Kaplan-Meier method and compared using log-rank
test. Multivariable Cox regression was used to identify
the independent predictors for overall survival. All the
p-values were two-tailed and p < 0.05 was considered
as significant. Data were analyzed by using SPSS version
20.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical demographics
We identified 120 patients managed surgically for renal
cancer with complete records on analysis, including
paraffin sections, surgery type, TNM status parameter,
and clinical symptoms at first encounter. All renal cancers
were clear cell type and median overall survival of the
enrolled subjects was 92.5 (IQR = 62.3–99.4) months. The
number of male patients was 83 (69%). The median age
was 56 (IQR = 50–65) years, and the median tumor size
was 5.0 cm (IQR = 3.5–7.0 cm). During the first diagnosis,
47 (39%) subjects suffered from clinical symptoms includ-
ing gross hematuria or palpable mass or significant weight
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loss. Radical nephrectomy was performed on 114 (95%)
patients (Table 1).
Overall survival in the subgroup of ABCG2 expression
IHC was used to detect the ABCG2 expression.
ABCG2(−) was found in 57 (48%) patients, ABCG2(+) in
52 (43%) patients, and ABCG2(++) in 11 (9.2%) patients
(Table 1). IHC-positive staining clear cell RCC cells
(brown) were mainly localized on the cell membrane,
showing different statuses of ABCG2 (Fig. 1). In order to
explore the expression of ABCG2 in non-RCC tissue, we
examined another 10 hydronephrosis patients with non-
cancer renal tissue and found that ABCG2 was negative
in these non-cancer renal parenchyma samples.
Kaplan-Meier analysis was used to evaluate overall
survival of all patients with clear cell RCC, grouped by
ABCG2 expression status. As shown in Fig. 2, median
overall survival was 93.2 (IQR = 88.6–96.3) months in
ABCG2(−) subgroup, 85.8 (IQR = 40.8–89.9) months in
ABCG2(+) subgroup, and 17.0 (IQR = 11.6–48.2) months
in ABCG2(++) subgroup. ABCG2 expression significantly
associated with the rate of five-year overall survival
(p < 0.001) (Table 2). The five-year survival rate was 95%
in ABCG2(−), 77% in ABCG2(+), and 27% in ABCG2(++)
subgroups, respectively (Fig. 2). Besides, there is a signifi-
cant association between ABCG2 expression and Fuhr-
man grade (p = 0.014). However other clinicopathological
parameters, including age, gender, symptoms, pT, lymph
node, and surgery type, failed to correlate with ABCG2
expression (Table 2).
In multivariable Cox regression analysis, besides
Fuhrman grade, ABCG2 expression was another inde-
pendent factor for overall survival (p < 0.001) when
incorporating other common clinical parameters, and
hazards ratio (HR) was 3.844 (95% CI: 1.919–7.700)
(Table 3).
ABCG2 expression in metastasis cohort
We also found ABCG2 expression significantly associated
with distant metastasis on first diagnosis (p = 0.001)
(Table 2). Patients with metastatic RCC were found during
the initial diagnosis, in which 12 patients were presented
as ABCG2(+) and 4 as ABCG2(++). The median overall
survival was 59.4 (IQR = 43.8–71.3) months and 16.8
(IQR = 14.5–19.8) months, respectively, p < 0.001.
ABCG2 expression in genitourinary tumors from TCGA
Based on the RNA-seq data, the mean value of ABCG2
expression is highest in the clear cell RCC group com-
pared to all the other genitourinary tumors available from
TCGA database (Additional file 1: Fig. S1, p < 0.001).
The TCGA data about ABCG2 in kidney clear cell
cancer are available on the scientific website http://
www.oncolnc.org, and http://mexpress.be/. There are
significant differences of mRNA levels of ABCG2 between
normal kidney tissue and tumor (p = <0.0001), and at
various stages (p = 0.024). Comparison of mRNA levels
of ABCG2 were similar in various grades (p = 0.503)
(Additional file 2: Fig. S2). There is also significant cor-
relation between overall survival and ABCG2 expres-
sion (Additional file 3: Fig. S3).
Discussion
The prognosis of RCC is difficult to predict, and thus, a
reliable biomarker is essential to guide the clinical
management. RCC is a chemotherapy-resistant and
radiotherapy-resistant malignant tumor, and the effi-
ciency of immunotherapy for this type of cancer is also
limited [4–6]. The introduction of tyrosine-kinase
inhibitors (TKIs) was considered as a breakthrough in
the treatment of metastatic RCC [16–18]. However,
most metastatic RCC patients administrated with TKIs
eventually yield to disease progression due to drug
resistance [19]. Several studies have been initiated in
an attempt to discover reliable prognostic biomarkers
Table 1 Patients and tumor characteristics
Parameters Value
Number of patients 120
Number of males (%) 83 (70%)
Median age at surgery (years) (IQR) 56 (50–65)
Median follow-up (months) (IQR) 92.5 (62.3–99.4)
Median tumor size (cm) (IQR) 5.0 (3.5–7.0)






Regional lymph node metastasis (TNM 2009) (%) 3 (2.5%)






Type of surgery (%)
Radical Nephrectomy 114 (95%)
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to predict the overall survival of RCC patients. Bui et al.
found that carbonic anhydrase IX and Ki67 are useful
prognostic biomarkers for RCC that can improve the
survival prediction and classification of renal cancer [20].
Several other biomarkers, such as carbonic anhydrase 9,
phosphatase, and tensin homologue deleted on chromo-
some 10, vimentin and p53, are also deemed to correlate
with overall survival in RCC patients when in combined
clinical parameters [21]. Vermaat et al. also reported that
serum amyloid α was a robust and independent prognosti-
cator for overall survival in RCC patients [22].
ABCG2 is a member of the ATP-binding cassette
transporters and an ATP-dependent membrane protein
predominantly expressed in the kidney [23]. ABCG2 is
highly expressed in cancer stem cells or side-population
cells and may protect the cells by pumping out xenobi-
otics, detrimental metabolites of oxidative stress, and
chemotherapeutic drugs [23–25]. Recent studies have
shown that ABCG2 has a vital role in the multidrug
resistance of cancer cells and may influence the overall
survival of tumor patients [26, 27]. Yoh et al. reported
that in advanced non-small cell lung cancer the response
rate to chemotherapy in patients with ABCG2(−) tumors
was 44%; however, in ABCG2(+) tumors, this rate de-
creased to 24%, accompanied by shorter overall survival
than ABCG2(−) patients (p = 0.004) [28]. Interestingly,
by utilizing the resources of TCGA database, we found
that the mean expression level of ABCG2 in clear cell
RCC is highest compared to all the other genitourinary
and gynecologic tumors (Additional file 1: Fig. S1,
p < 0.001). So we speculate that ABCG2 minght be a
crucial marker and regulator of clear cell RCC progres-
sion. Therefore, we evaluated the prognostic impact of
ABCG2 expression on overall survival in clear cell RCC
patients managed with renal surgery.
In the present study, we found that ABCG2 expression
highly correlated with overall survival in patients with
clear cell RCC. Overall survival is considered as the most
valuable endpoint in terms of assessing the prognostic
outcome in RCC patients, and the analysis of this par-
ameter is a strength of the study. Survival curves (Fig. 2)
showed a significant difference of overall survival among
various degrees of expression of ABCG2, p < 0.001. The
stronger the ABCG2 expression, poorer the overall
survival. The median overall survival was 93.2, 85.8,
and 17.0 months in ABCG2(−), (+), and (++) subgroups,
respectively. The five-year survival rate was 95%, 77%, and
27% in ABCG2(−), (+), and (++) subgroups, respectively.
Based on the routine practice in our institution, interferon
alpha or TKIs (Sorafenib or Sunitinib) were used as adju-
vant therapeutics for patients with RCC after surgery; the
efficacy of TKIs was reported as promising [16–18]. How-
ever, in our study, 19 patients with metastatic RCC treated
with TKIs showed a poor median overall survival.
Moreover, we analyzed the correlation of ABCG2
expression of these 19 patients with metastatic RCC.
The median overall survival was 59.4 (IQR = 43.8–71.3)
Fig. 1 H&E and IHC of the cell membrane in clear cell RCC show the status of ABCG2 (10 × 20). a H&E staining of the RCC case. b RCC was
ABCG2(−), no membrane staining could be seen. c RCC was ABCG2(+), weak membrane staining. d RCC was ABCG2(++), moderate to strong
membrane staining. e Scale bar = 50 μm, and f. Scale Bar = 200 μm
Fig. 2 Kaplan-Meier survival for different subgroups based on the
expression of ABCG2. A significant difference of overall survival among
various degrees of expression of ABCG2 is observed, p < 0.001
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months in ABCG2(+) cohort and 16.8 (IQR = 14.5–19.8)
months in ABCG2(++) cohort, p < 0.001. The predispos-
ition indicated that stronger the ABCG2 expression,
poorer the prognosis. The correlation necessitates further
studies. Interestingly, we found that ABCG2 expression
significantly correlated with Fuhrman grade in renal cell
carcinoma. This may be associated with the protein ex-
pression of the nucleus in malignant renal cell. Higher
mRNA levels of ABCG2 gene was found in more malig-
nant pancreatic cell [29] and we need to elucidate this in
further research in RCC. In the multivariate analysis,
ABCG2 and Fuhrman grade were significant predictors
for overall survival (p < 0.001) when combined with the
TNM status parameters.
Due to the limited knowledge and conditions, the
mechanism of ABCG2 in RCC is not fully elucidated.
Szakacs et al. reported that ABCG2 played a vital role in
the multidrug resistance of cancer cells, thereby influen-
cing the overall survival [27]. Hypoxia is the key step in
the development and progression of RCC and is mainly
regulated by Von Hippel-Lindau, an important tumor
suppressor gene. Besides, hypoxia is verified to affect the
Table 2 Associations between ABCG2 expression and clinical parameters in patients with clear cell RCC
Parameters Value ABCG2(−) ABCG2(+) ABCG2(++) P
Gender Female 16 (28%) 17 (33%) 4 (36%) 0.510
Male 41 (72%) 35 (67%) 7 (64%)
Age at surgery (years) <60 4172%) 33 (63%) 4 (36%) 0.054
≥60 16 (28%) 19 (37%) 7 (64%)
Symptoms on first diagnosis Negative 36 (63%) 33 (63%) 4 (36%) 0.351
Positive 21 (37%) 19 (37%) 7 (64%)
pT T1a 23 (40%) 13 (25%) 1 (9%) 0.180
T1b 22 (39%) 28 (54%) 5 (45%)
T2 9 (16%) 6 (12%) 3 (27%)
T3 3 (5%) 5 (10%) 2 (18%)
Regional lymph node metastasis Negative 56 (98%) 51 (98%) 9 (82%) 0.103
Positive 1 (2%) 1 (2%) 2 (18%)
Distant metastasis on first diagnosis Negative 54 (95%) 40 (77%) 7 (64%) 0.001*
Positive 3 (5%) 12 (23%) 4 (36%)
Fuhrman grade 1 14 (25%) 4 (8%) 0 (0%) 0.014*
2 31 (54%) 35 (67%) 4 (36%)
3 9 (16%) 11 (21%) 5 (45%)
4 3 (5%) 2 (4%) 2 (18%)
Five-year survival Alive 53 (93%) 40 (77%) 3 (27%) <0.001*
Deceased 4 (7%) 12 (23%) 8 (73%)
Surgery type Radical Nephrectomy 2 (4%) 4 (8%) 0 (0%) 0.441
Partial Nephrectomy 55 (96%) 48 (92%) 11 (100%)
Table 3 Multivariable Cox regression for OS in patients with clear cell RCC
Parameters HR lower 95% CI upper 95% CI P
Gender 1.168 0.469 2.908 0.686
Age at surgery 1.053 0.999 1.110 0.343
Symptoms on first diagnosis 1.610 0.577 4.493 0.468
Clinical tumor size 0.827 0.615 1.111 0.471
pT 2.357 0.432 12.866 0.352
Regional lymph node metastasis 0.404 0.110 1.485 0.220
Distant metastasis on first diagnosis 0.979 0.317 3.019 0.783
ABCG2 3.375 1.704 6.687 0.000*
Fuhrman grade 3.488 1.491 8.161 0.004*
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ATP-binding cassette transporter family, including ABCG2
[30]. In the pancreatic cancer, there are significant cor-
relations between mRNA levels of ABCG2 and clinical
outcomes [29]. Many researches are arising to detect
the mechanism of ABCG2 in drug resistance in other
malignancies, while, to our knowledge, studies regard-
ing ABCG2 expression in RCC leading to therapeutic
resistance are lacking. Till date, there is one report by
Korenaga and colleagues indicating that the ABCG2
polymorphism (C421A) is a risk factor for developing
non-papillary RCC [31]. So it’s necessary to make further
study in the field of ABCG2 effect on drug resistance in
RCC. With the advent of efficient inhibitors of ABCG2,
the combination strategies of targeted drugs and ABCG2
inhibitors might provide the promising therapeutic effect.
The detection ABCG2 expression by IHC staining is
clinically valuable. Improved diagnostic techniques aimed
at the selection of RCC patients with less expression of
ABCG2 might result in more successful outcomes. For
example, the RCC patients with highly expressed ABCG2
require more care after surgery and intensive follow-up.
Moreover, IHC staining is a common and economical
method to detect ABCG2 and could be widely used in
clinical management. Therefore, ABCG2 could be utilized
in most medical institutions.
While this study comprised a moderate size of patients
with extended follow-up, it is also retrospective and
derived from a single tertiary-care center, which could
impact the generalizability. Another limitation is that the
paraffin sections were preserved for a prolonged duration
that may affect the IHC staining to a certain degree.
Conclusions
ABCG2 is a significant and independent prognostic
marker of overall survival in patients with clear cell RCC
managed by renal surgery, and its high expression is
correlated with poor overall survival and increased
metastasis. This will be conducive to further research
of ABCG2 at molecular level as well as gene level for
the drug resistance in kidney cancer. IHC staining for
ABCG2 could be monitored routinely in clinical man-
agement. Moreover, further pre-clinical evaluations for
the mechanism of ABCG2 in RCC are essential.
Additional files
Additional file 1: Fig. S1. The RNA-seq V2 data was downloaded from
TCGA database and analyzed by the cBioPortal-MSKCC tool. Statistical analysis
was performed between clear cell RCC and all the other genitourinary tumors
available from TCGA database using unpaired t-tests and nonparametric test.
(Significance was considered as * = p < 0.5; **p = < 0.01; *** = p < 0.001).
UCEC (Uterine Corpus Endometrial Carcinoma) N = 177. BUC (Bladder
Urothelial Carcinoma) N = 408. OSC (Ovarian Serous Cystadenocarcinoma)
N = 122. KRPCC (Kidney Renal Papillary Cell Carcinoma) N = 291. UC (Uterine
Carcinosarcoma) N = 57. ADC (Adrenocortical Carcinoma (TCGA, Provisional)
N = 79. KCP (Kidney Chromophobe) N = 66. Clear Cell RCC (Kidney Renal
Clear Cell Carcinoma) N = 598. (PDF 58 kb)
Additional file 2: Fig. S2. The mRNA data was downloaded from TCGA
database on the public scientific website: http://mexpress.be/ and drafted
into graphics. A, comparison of mRNA levels of ABCG2 between normal
kidney tissue and tumor, p = <0.0001. B, comparison of mRNA levels of
ABCG2 at different stages, p = 0.024. C, comparison of mRNA levels of
ABCG2 in different grades, p = 0.503. KIRC(Kidney renal clear cell
carcinoma). (PDF 381 kb)
Additional file 3: Fig. S3. The TCGA data about ABCG2 expression and
overall survival in Kidney clear cancer were available on the website:
http://www.oncolnc.org. Kaplan-Meier survival was significant for various
groups based on the expression of ABCG2, p < 0.001. (PDF 180 kb)
Abbreviation
ABCG2: ATP-binding cassette sub-family G member 2; ADC: Adrenocortical
Carcinoma; BUC: Bladder Urothelial Carcinoma; CI: Confidence Interval;
HR: Hazards Ratio; IHC: Immunohistochemistry; IQR: Interquartile Range;
KCP: Kidney Chromophobe; KIRC: Kidney Renal Clear cell carcinoma;
KRPCC: Kidney Renal Papillary Cell Carcinoma; OSC : Ovarian Serous
Cystadenocarcinoma; RCC: Renal Cell Carcinoma; TCGA: The Cancer
Genome Atlas; TKIs: Tyrosine-Kinase Inhibitors; UC: Uterine Carcinosarcoma;
UCEC: Uterine Corpus Endometrial Carcinoma
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